<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631070</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-536-MDS-001</org_study_id>
    <nct_id>NCT02631070</nct_id>
  </id_info>
  <brief_title>A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes</brief_title>
  <acronym>MEDALIST</acronym>
  <official_title>A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to the IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acceleron Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted in compliance with the International Council on Harmonisation
      (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good
      Clinical Practice (GCP) and applicable regulatory requirements.

      This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to
      determine the efficacy and safety of luspatercept (ACE-536) versus placebo in subjects with
      anemia due to IPSS-R very low, low, or intermediate MDS with ring sideroblasts who require
      RBC transfusions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anemia is considered to be one of the most prevalent cytopenias in patients who have
      myelodysplastic syndromes, an umbrella term used to describe disorders relating to the
      ineffective production of red blood cells, white blood cells, and/or platelets. Ranging in
      severity from mild (asymptomatic) to severe, anemia can result in patients requiring regular
      red blood cell (RBC) transfusions, which can lead to further complications from iron
      overload. The goal of this study is to assess the safety and efficacy of luspatercept versus
      placebo in anemic patients who are categorized as International Prognostic Scoring
      System-Revised (IPSS-R) very low, low, or intermediate risk Myelodysplastic syndrome (MDS),
      have ring sideroblasts present, and require constant RBC transfusions. The design of the
      study will allow a period of initial randomization of patients into either the luspatercept
      or placebo arm, followed by a double-blind treatment period, and then an MDS disease
      assessment visit. For those patients that are determined to be experiencing clinical benefit
      as judged from the study Investigator by this disease assessment visit, they will be
      permitted to enter the double-blind Extension Phase of the study. Once patients are
      discontinued from study treatment, they will enter a post treatment follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 9, 2016</start_date>
  <completion_date type="Anticipated">November 5, 2020</completion_date>
  <primary_completion_date type="Actual">November 21, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Red Blood Cell Transfusion Independence (RBC-TI) ≥ 8 weeks</measure>
    <time_frame>Week 1 through week 24</time_frame>
    <description>Proportion of subjects who are red blood cell (RBC) transfusion free over any consecutive 56-day period within week 1 through week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell Transfusion Independence (RBC-TI) ≥ 12 weeks</measure>
    <time_frame>Up to approximately 48 weeks</time_frame>
    <description>Proportion of subjects who are Red blood cell (RBC) transfusion free over any consecutive 84-day period within week 1 through 24 and week 1 through 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell Transfusion Independence (RBC-TI) ≥ 8 weeks</measure>
    <time_frame>Up to approximately 48 weeks</time_frame>
    <description>Proportion of subjects who are Red blood cell (RBC) transfusion free over any consecutive 56-day period within week 1 through week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in red blood cell (RBC) units transfused over 16 weeks</measure>
    <time_frame>Up to approximately 48 weeks</time_frame>
    <description>Mean change in total Red blood cell (RBC) units transfused over a fixed 16-week period within week 8 trough 24 and week 32 through 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving Modified hematologic improvement - erythroid (mHI-E) per International Working Group (IWG) over any consecutive 56 days</measure>
    <time_frame>Up to approximately 48 weeks</time_frame>
    <description>Proportion of subjects achieving modified Hematological improvement-erythroid (HI-E) over any consecutive 56-day period during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean hemoglobin increase ≥ 1.0 g/dL</measure>
    <time_frame>Up to approximately 48 weeks</time_frame>
    <description>Proportion of subjects achieving hemoglobin (Hgb) increase from baseline ≥ 1.0 g/dL over any consecutive 56-day period in absence of Red blood cell (RBC) transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Red Blood Cell Transfusion Independence (RBC-TI)</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
    <description>Maximum duration of red blood cell (RBC) transfusion independence for subjects who achieve RBC TI ≥ 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EORTC QLQ-C30 score</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
    <description>Change in EORTC QLQ-C30 scores per scheduled visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic improvement - neutrophils (HI-N) per International Working Group (IWG)</measure>
    <time_frame>Up to approximately 48 weeks</time_frame>
    <description>Proportion of subjects achieving HI-N over any consecutive 56-day period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean decrease in serum ferritin</measure>
    <time_frame>Up to approximately 48 weeks</time_frame>
    <description>Change in serum ferritin over scheduled assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean decrease in iron chelation therapy (ICT) use</measure>
    <time_frame>Up to approximately 48 weeks</time_frame>
    <description>The change in daily dose for each subject is calculated as the difference of post-baseline mean daily dose and baseline mean daily dose. Analysis of covariance (ANCOVA) will be used to compare the treatment difference between groups, with the stratification factors and baseline ICT value as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to red blood cell transfusion independence (RBC-TI)</measure>
    <time_frame>Up to approximately 48 weeks</time_frame>
    <description>Time between randomization and the date onset of TI is first observed (ie, Day 1 of 56 days without any RBC transfusions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects progressing to acute myeloid leukemia (AML)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Assessments/measurements that were collected in different units of measure will be aggregated and presented by standard units for the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression to acute myeloid leukemia (AML)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Is defined as the time between randomization and first diagnosis of AML as per WHO classification of ≥ 20% blasts in peripheral blood or bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
    <description>Overall survival is defined as the time from date of randomization to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
    <description>Type, frequency, severity of AEs and relationship of AEs to luspatercept/placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of anti-drug antibodies (ADA)</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
    <description>Will be collected for assessment of anti-drug antibodies (ADA) against luspatercept in serum in all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics ‐ Cmax</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Maximum observed concentration in plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">229</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Experimental Arm - Luspatercept (ACE-536)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous injection every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luspatercept</intervention_name>
    <arm_group_label>Experimental Arm - Luspatercept (ACE-536)</arm_group_label>
    <other_name>ACE-536</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Control Arm: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must satisfy the following criteria to be enrolled in the study:

          1. Subject is ≥ 18 years of age the time of signing the informed consent form (ICF).

          2. Documented diagnosis of MDS according to World Health Organization (WHO)/French
             American British (FAB) classification that meets IPSS R classification of very low,
             low, or intermediate risk disease, and:

             Ring sideroblast ≥ 15% of erythroid precursors in bone marrow or ≥ 5% (but &lt; 15%) if
             SF3B1 mutation is present.

          3. Requires red blood cell RBC transfusions

          4. Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2

          5. Subjects who are refractory/intolerant/ineligible to prior ESA treatment, defined as:

               -  Refractory to prior Erythropoiesis- stimulating agents(ESA) treatment:
                  documentation of non-response or response that is no longer maintained to prior
                  ESA-containing regimen, either as single agent or combination (eg, with G-CSF);
                  ESA regimen must have been either recombinant human erythropoietin (rHu EPO) ≥
                  40,000 IU/wk for at least 8 doses or equivalent OR darbepoetin alpha ≥ 500 μg Q3W
                  for at least 4 doses or equivalent

               -  Intolerant to prior ESA treatment: documentation of discontinuation of prior
                  ESA-containing regimen, either as single agent or combination (eg, with G-CSF),
                  at any time after introduction due to intolerance or an adverse event

               -  ESA ineligible: low chance of response to ESA base on endogenous serum
                  erythropoietin level &gt; 200 U/L for subjects not previously treated with ESAs

        Exclusion Criteria:

          -  The presence of any of the following will exclude a subject from enrollment:

               1. Prior therapy with disease modifying agents for underlying MDS disease

               2. Previously treated with either luspatercept (ACE-536) or sotatercept (ACE-011)

               3. MDS associated with del 5q cytogenetic abnormality

               4. Secondary MDS, ie, MDS that is known to have arisen as the result of chemical
                  injury or treatment with chemotherapy and/or radiation for other diseases.

               5. Known clinically significant anemia due to iron, vitamin B12, or folate
                  deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal
                  bleeding

          -  iron deficiency to be determined by a bone marrow aspirate stain for iron, calculated
             transferrin saturation (iron/total iron binding capacity) ≤ 20%, or serum ferritin ≤
             15 μg/L 6. Prior allogeneic or autologous stem cell transplant 7. Known history of
             diagnosis of Acute myeloid leukemia (AML) 8. Use of any of the following within 5
             weeks prior to randomization:

               -  anticancer cytotoxic chemotherapeutic agent or treatment

               -  corticosteroid, except for subjects on a stable or decreasing dose for ≥ 1 week
                  prior to randomization for medical conditions other than MDS

               -  iron-chelating agents, except for subjects on a stable or decreasing dose for at
                  least 8 weeks prior to randomization

               -  other RBC hematopoietic growth factors (eg, Interleukin-3)

               -  investigational drug or device, or approved therapy for investigational use. If
                  the half-life of the previous investigational product is known, use within 5
                  times the half-life prior to randomization or within 5 weeks, whichever is longer
                  is excluded.

                  9. Prior history of malignancies, other than MDS, unless the subject has been
                  free of the disease (including completion of any active or adjuvant treatment for
                  prior malignancy) for ≥ 5 years. However, subjects with the following
                  history/concurrent conditions are allowed:

               -  Basal or squamous cell carcinoma of the skin

               -  Carcinoma in situ of the cervix

               -  Carcinoma in situ of the breast

               -  Incidental histologic finding of prostate cancer (T1a or T1b using the tumor,
                  nodes, metastasis [TNM] clinical staging system)

                  10. Major surgery within 8 weeks prior to randomization. Subjects must have
                  completely recovered from any previous surgery prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aziz Benzohra, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Institutions</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center Albert Einstein Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia-Presbyterian Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Klina</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan AV Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussels</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires UCL de Mont-Godine</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hotel</name>
      <address>
        <city>Grenoble Cedex 09</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille cedex</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice Archet I</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud Hematologie</name>
      <address>
        <city>Pierre-Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl Gustav Carus an der TU Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien Hospital</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santi Antonio Biagio E Cesare Arrigo</name>
      <address>
        <city>Allessandria</city>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale Lecce</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Bianchi Melacrino Morelli</name>
      <address>
        <city>Reggio, Calabria</city>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione PTV Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2135</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces</name>
      <address>
        <city>Barakaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia-Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08901</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhus</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skanes Universitetssjukhus Lund</name>
      <address>
        <city>Lund</city>
        <zip>222 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cukurova University Medical Faculty Balcali Hospital</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University Medical Faculty Cebeci Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa Medical Faculty Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi Hastanesi</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Headington</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guys Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings Mill Hospital</name>
      <address>
        <city>Sutton in Ashfield</city>
        <zip>NG17 4SL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <disposition_first_submitted>May 16, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>May 16, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 18, 2018</disposition_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Luspatercept</keyword>
  <keyword>Transfusion dependent</keyword>
  <keyword>Lower risk</keyword>
  <keyword>Low risk</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>ESA refractory</keyword>
  <keyword>ESA intolerant</keyword>
  <keyword>ESA ineligible</keyword>
  <keyword>ACE-536</keyword>
  <keyword>Anemia</keyword>
  <keyword>Ring Sideroblasts</keyword>
  <keyword>Require Red Blood Cell Transfusions</keyword>
  <keyword>MEDALIST</keyword>
  <keyword>MDS</keyword>
  <keyword>IPSS-R very low/IPSS-R low/IPSS-R intermediate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

